Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Wen-Zhao, Wang, Qun, Mao, Wei-Min, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yang, Jin-Ji, Yan, Hong-Hong, Yang, Xue-Ning, Liu, Si-Yang, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078324/
https://www.ncbi.nlm.nih.gov/pubmed/33332190
http://dx.doi.org/10.1200/JCO.20.01820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078324/
https://www.ncbi.nlm.nih.gov/pubmed/33332190
http://dx.doi.org/10.1200/JCO.20.01820

Ejemplares similares